These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24075577)

  • 1. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
    Loriot Y; Fizazi K
    Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
    Pal SK; Sartor O
    Nat Rev Clin Oncol; 2014 Sep; 11(9):504-6. PubMed ID: 25073005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
    Miller K; Albers P; Eichenauer R; Geiges G; Grimm MO; König F; Mickisch G; Pfister D; Schwentner C; Suttmann H; Zastrow S
    Urologe A; 2014 May; 53(5):710-4. PubMed ID: 24806804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
    Francini E; Roviello G
    Tumour Biol; 2014 Aug; 35(8):7391-2. PubMed ID: 24874054
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
    Thomson D; Charnley N; Parikh O
    Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
    Lorente D; Bianchini D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; De Bono JS
    Eur J Cancer; 2014 Mar; 50(5):1042-3. PubMed ID: 24433842
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
    Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
    Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
    Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
    Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?
    Hélissey C; Rouanne M; Arnaud FX; Le Moulec S
    Anticancer Drugs; 2015 Mar; 26(3):367-70. PubMed ID: 25486600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
    Brodszky V; Péntek M; Baji P; Rencz F; Géczi L; Szûcs M; Berczi C; Gulácsi L
    Magy Onkol; 2014 Sep; 58(3):189-97. PubMed ID: 25260083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
    Pal SK; Lewis B; Sartor O
    Urol Clin North Am; 2012 Nov; 39(4):583-91. PubMed ID: 23084533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    Bahl A
    Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 16. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer in 2014: The year chemotherapy finally gets some respect!
    Saad F
    Nat Rev Urol; 2015 Feb; 12(2):71-2. PubMed ID: 25600097
    [No Abstract]   [Full Text] [Related]  

  • 18. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
    Albiges L; Loriot Y; Massard C; Fizazi K
    Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
    Goldkorn A; Aparicio AM; Quinn DI
    Ann Oncol; 2013 Jul; 24(7):1717-1720. PubMed ID: 23798673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.